Orexo: Worst-Case Scenario Averted
Edison | Nov 28, 2016 04:46AM ET
The court ruling upholding the validity of the Orexo AB (ST:ORX) ’996 Zubsolv patent precludes Actavis (NYSE:AGN) from launching a generic before September 2019. Orexo has 30 days to decide whether to appeal the court decision that a second patent (’330 with 2032 expiry) is invalid. A worst-case scenario allowing imminent launch of Actavis generic(s) has been averted. Zubsolv’s IP portfolio includes two additional patents (’900 and ’421) that extend to 2032, which coupled with the prospect of an appeal on ’330, means that significant hurdles remain ahead of Actavis generic launch.
Multi-layer IP strategy for Zubsolv
Actavis is the only company to file ANDAs for generic Zubsolv to date. The recent ruling relates to the June 2016 court hearing concerning the first ANDA (filed 2014 covering Zubsolv 1.4mg and 5.7mg); the court decision upheld the validity of the 8,454,996 US patent but found 8,940,330 invalid. Since the first ANDA filing, the FDA has approved four further Zubsolv dose strengths and two new patents have been issued (9,259,421 and 9,439,900). Actavis’s second ANDA was filed in 2015; Orexo responded by initiating two additional infringement suits. The first suit has an October 2017 trial date; the second (related to ’421) is pending a court date.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.